Clinical and biological effects of an agonist anti-CD40 antibody: a Cancer Research UK phase I study.

@article{Johnson2015ClinicalAB,
  title={Clinical and biological effects of an agonist anti-CD40 antibody: a Cancer Research UK phase I study.},
  author={Peter W M Johnson and Ruth Challis and Ferdousi Chowdhury and Yifang Gao and Melanie Harvey and Tom Geldart and Paul F. Kerr and Claude H. T. Chan and Anna Jo Bodurtha Smith and Neil M. Steven and Ceri E Edwards and Margaret R Ashton-Key and Elisabeth Hodges and Alison L. Tutt and Christian H Ottensmeier and Martin John Glennie and Anthony Peter Williams},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2015},
  volume={21 6},
  pages={
          1321-8
        }
}
PURPOSE This phase I study aimed to establish the biologic effects and MTD of the agonistic IgG1 chimeric anti-CD40 antibody ChiLob7/4 in patients (pts) with a range of CD40-expressing solid tumors and diffuse large B-cell lymphoma, resistant to conventional therapy. Potential mechanisms of action for agonistic anti-CD40 include direct cytotoxic effects on tumor cells and conditioning of antigen-presenting cells. EXPERIMENTAL DESIGN ChiLob7/4 was given by IV infusion weekly for 4 doses at a… CONTINUE READING
Tweets
This paper has been referenced on Twitter 7 times. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-10 OF 14 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 20 REFERENCES

Interaction with FcgammaRIIB is critical for the agonistic activity of antiCD40 monoclonal antibody

  • AL White, HT Chan, A Roghanian, RR French, CI Mockridge, AL Tutt
  • J Immunol
  • 2011
1 Excerpt

Similar Papers

Loading similar papers…